Search Results
Mar 02, 2026, 05:07 ET 國內首個「AI+RNA」小分子創新藥完成首例患者給藥，晶泰科技與ReviR共研「一藥多治」管線RTX-117瞄準千億級神經退行性疾病市場
潛力及前沿進展的創新藥，有望填補巨大的治療市場空白，撬動全球超100億美元的治療市場。其「一藥多治」策略還可通過同一分子在不同適應症中的相互驗證，顯著提升該管線開發的成功率。RTX-117 通過抑制異常激活的ISR通路，恢復 mRNA 的正常翻譯，達到從分子根源上治療疾病的效果。該通路不僅對VWM 和 CMT 的治療至關重要，還被認為與漸凍症（ALS）、帕金森病（PD）、阿爾茨海默病（AD）以及腦損傷等多種神經系統疾病密切相關。隨著其I期臨床實驗的有序推進，未來，RTX-117有望進一步拓展至更多適應症，潛在覆蓋人群預計超5000萬。在RTX-117
More news about: 晶泰科技
Feb 26, 2026, 16:09 ET Head and Neck Cancer Therapeutics Market to Reach USD 2.6 Billion by 2032, Driven by Immunotherapy and Precision Oncology - Credence Research Inc.
https://www.credenceresearch.com/report/us-monoclonal-antibodies-therapeutics-marketmRNA Therapeutics Market https://www.credenceresearch.com/report/mrna-therapeutics-marketBrain Metastasis Therapeutics Market
More news about: Credence Research Inc.
Feb 26, 2026, 11:30 ET Children's Hospital of Philadelphia and Penn Medicine Launch First CRISPR-Based Platform to Pinpoint Drivers of Acute Myeloid Leukemia in Patient Cells
pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.The University of Pennsylvania Health System's patient care facilities stretch from the Susquehanna River
More news about: Children's Hospital of Philadelphia
Feb 26, 2026, 08:00 ET SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
clinical advancement of a broadly protective sarbecovirus vaccine supported by the Gates Foundation and CEPI; and the establishment of next-generation mRNA platform strategies. Through these efforts, the company aims to expand its leadership beyond Korea and into the global vaccine market.About
More news about: SK bioscience
Feb 25, 2026, 21:00 ET Argo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting
2. Current treatments require frequent dosing, highlighting the need for long-acting, preventive therapies. BW-20805 targets human hepatic PKK mRNA to inhibit PKK gene expression, offering the potential for effective prevention of HAE attacks with a significant and longer-lasting therapeutic effect.About
More news about: Argo Biopharmaceutical Co., Ltd
Feb 25, 2026, 09:00 ET 揭示腸道細菌與癌症治療關聯性的研究榮膺 Bial 生物醫學獎，獲頒 35 萬歐元獎金
歷屆獲得表彰的傑出研究成果，後來都贏得了蜚聲國際的科學獎項。 值得注意的是，兩位曾於 2021 年獲得「BIAL 生物醫學獎」的科學家 Katalin Karikó 與 Drew Weissman，榮獲了 2023 年諾貝爾生理學或醫學獎以表彰他們的發現，讓研發能有效防治 COVID-19 的 mRNA 疫苗成為現實。
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET 장내 박테리아와 암 치료의 연관성 규명한 연구, 비알 생의학상 수상 및 35만 유로 상금 받아
접수됐다. 과거 수상 연구들 가운데는 이후 국제적으로 권위 있는 과학상을 수상한 사례도 있다. 특히 2021년 비알 생의학상을 수상한 카탈린 카리코(Katalin Karikó)와 드루 와이스먼(Drew Weissman)은 코로나19 예방을 위한 효과적인 mRNA 기반 백신 개발에 기여한 공로로 2023년 노벨 생리의학상을 수상했다.사진 - https://mma.prnewswire.com/media/2919779/Bial_Award.jpg로고
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns €350,000 prize
Karikó and Drew Weissman, were awarded the 2023 Nobel Prize in Physiology or Medicine for their discoveries that enabled the development of effective mRNA-based vaccines to prevent COVID ‑ 19.Photo - https://mma.prnewswire.com/media/2919779/Bial_Award.jpgLogo
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Descoberta ligando bactérias intestinais ao tratamento do câncer vence o Prêmio Bial em Biomedicina e recebe € 350.000
receberam o Prêmio Nobel de Fisiologia ou Medicina de 2023 por suas descobertas que possibilitaram o desenvolvimento de vacinas eficazes baseadas em mRNA para prevenir a COVID-19.Foto - https://mma.prnewswire.com/media/2919779/Bial_Award.jpgLogotipo
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Entdeckung zum Zusammenhang zwischen Darmbakterien und Krebstherapie gewinnt den Bial Award in Biomedicine und erhält 350.000 Euro Preisgeld
Jahres 2021, Katalin Karikó und Drew Weissman, 2023 den Nobelpreis für Physiologie oder Medizin für ihre Entdeckungen, die die Entwicklung wirksamer mRNA-basierter Impfstoffe zur Prävention von COVID-19 ermöglichten.Foto -
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns €350,000 prize
Karikó and Drew Weissman, were awarded the 2023 Nobel Prize in Physiology or Medicine for their discoveries that enabled the development of effective mRNA-based vaccines to prevent COVID ‑ 19.Photo - https://mma.prnewswire.com/media/2919779/Bial_Award.jpgLogo
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
clinical trials this year. The company now has more than 25 ongoing Phase 2 or 3 oncology trials spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies."We see 2026 as a year when science translates into tangible results," said Prof. Ugur Sahin, M.D., CEO and Co-Founder
More news about: Equity Insider
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
of MBNL protein function is caused by (1), reduced expression of MBNL proteins due to miR-23b upregulation and (2) MBNL sequestration in toxic DMPK mRNA, which leads to a spliceopathy, and is the cause of symptomatology in DM1 patients. "These data support miR-23b inhibition as a compelling, disease-modifying
More news about: ARTHEx Biotech
Feb 24, 2026, 08:30 ET Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership
enables rapid, end-to-end design of precisely engineered mRNA molecules that are optimized for enhanced translation, stability, immune evasion, and tissue-specific expression. The platform also efficiently identifies optimal target sites within mRNA for maximally effective ASO/siRNA design. Therna's technology
More news about: Therna Biosciences
Feb 24, 2026, 08:00 ET Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)
the mRNA sequences of Klotho and 8 other genes described in the scientific literature as being associated with longevity and healthy lifespan. Since Klotho induces the expression of several of these genes, Klotho is of primary interest. Complementary with the genetic sequence analysis, the mRNA analysis
More news about: Klotho Neurosciences, Inc.
Feb 24, 2026, 02:00 ET etherna's intratumoral mRNA/LNP platform advances to clinical testing in nonmelanoma skin cancer led by Almirall
to see rapid progress of our collaboration with etherna based on their mRNA and LNP capabilities." About etherna etherna is a leading technology platform company pioneering the development of mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to
More news about: etherna
Feb 23, 2026, 10:30 ET Viral Vectors and Plasmid DNA Manufacturing Market to Reach $34.0 billion by 2033 at 20.4% CAGR: Allied Market Research
is an important raw material for both viral vector production and non-viral gene delivery approaches. It is also increasingly used in DNA vaccines, mRNA production workflows, and emerging gene-editing technologies. This surge in scope of applications is driving faster demand compared to traditional viral
More news about: Allied Market Research
Feb 22, 2026, 19:30 ET 以AI節省90%實驗！晶泰科技與堯唐生物聯手破局 mRNA 葯千億級黃金賽道
vivo CAR-T、腫瘤疫苗等多個高難度藥物研發場景中，不同於現有模型需要合成檢測上百條序列的篩選規模，晶泰科技平均僅需設計約10條序列，即可篩選出蛋白表達量與穩定性大幅提升的全新分子，節省 90% 以上的實驗需求；同時兼顧長效性與安全性，極大地提高了藥物研發效率、降低研發成本。晶泰科技的 AI mRNA 序列設計平台憑藉精準的設計能力與高效的交付能力，為mRNA藥物研發提供更具競爭優勢的解決方案。此次合作是雙方基於技術優勢與行業資源的強強聯合——堯唐生物是國際上體內基因編輯藥物進入臨床階段管線最多的公司，其自主研發的體內鹼基編輯藥物已在中美兩地獲批臨床試驗。晶泰科技的
More news about: 晶泰科技
Feb 18, 2026, 17:00 ET The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
address the underlying genetic root cause of DM1 by reducing total levels of the toxic, DMPK (myotonic dystrophy protein kinase) mRNA. The accumulation of these toxic mRNA sequester key RNA-regulatory proteins that subsequently lead to missplicing of several downstream genes, resulting in the diverse
More news about: Avidity Biosciences, Inc.
Feb 18, 2026, 10:01 ET Autogenous Vaccines Market to Reach US$ 451.5 Million by 2033; Expands Amid Rising Livestock Health Needs and Precision Disease Control - Persistence Market Research
Global Flu RNA Vaccines Market by Vaccine Type (Non‑replicating mRNA, Self‑replicating mRNA, Dendritic cell mRNA, Others), by Application (Hospitals, Vaccination centers, Clinics, Pharmacies), by Service, by Distribution Channel, and Regional
More news about: Persistence Market Research Pvt. Ltd.
Feb 17, 2026, 09:00 ET Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study
patient-derived double-loaded dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.The unique double-loading approach,
More news about: Diakonos Oncology
Feb 17, 2026, 07:00 ET Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research
More news about: Scinai Immunotherapeutics Ltd.
Feb 11, 2026, 04:01 ET Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization
More news about: Akeso, Inc.
Feb 09, 2026, 08:10 ET CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines
partnerships.In Malaysia, with the construction of vaccine fill-and-finish facility, CanSinoBIO is collaborating with local institutions to develop multivalent mRNA influenza vaccine, contributing to global influenza prevention and control efforts."The WGS provides us a vital platform for deepening
More news about: CanSinoBIO
Feb 09, 2026, 08:03 ET CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines
partnerships.In Malaysia, with the construction of vaccine fill-and-finish facility, CanSinoBIO is collaborating with local institutions to develop multivalent mRNA influenza vaccine, contributing to global influenza prevention and control efforts."The WGS provides us a vital platform for deepening
More news about: CanSinoBIO